Janus Henderson Group PLC Has $414.78 Million Stock Holdings in Revolution Medicines, Inc. (NASDAQ:RVMD)

Janus Henderson Group PLC boosted its holdings in Revolution Medicines, Inc. (NASDAQ:RVMD - Free Report) by 54.5% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 9,483,999 shares of the company's stock after acquiring an additional 3,346,755 shares during the period. Janus Henderson Group PLC owned about 5.64% of Revolution Medicines worth $414,777,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of RVMD. IFP Advisors Inc bought a new stake in shares of Revolution Medicines during the fourth quarter valued at approximately $34,000. Sterling Capital Management LLC raised its holdings in shares of Revolution Medicines by 588.7% during the fourth quarter. Sterling Capital Management LLC now owns 1,956 shares of the company's stock valued at $86,000 after buying an additional 1,672 shares during the last quarter. Farther Finance Advisors LLC raised its holdings in shares of Revolution Medicines by 368.3% during the fourth quarter. Farther Finance Advisors LLC now owns 2,051 shares of the company's stock valued at $90,000 after buying an additional 1,613 shares during the last quarter. Kapitalo Investimentos Ltda bought a new stake in shares of Revolution Medicines during the fourth quarter valued at approximately $104,000. Finally, Daiwa Securities Group Inc. raised its holdings in shares of Revolution Medicines by 521.8% during the fourth quarter. Daiwa Securities Group Inc. now owns 3,787 shares of the company's stock valued at $165,000 after buying an additional 3,178 shares during the last quarter. Institutional investors own 94.34% of the company's stock.

Wall Street Analysts Forecast Growth

A number of research firms have recently weighed in on RVMD. Guggenheim cut their price target on Revolution Medicines from $87.00 to $80.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. HC Wainwright reiterated a "buy" rating and set a $72.00 price objective (down previously from $73.00) on shares of Revolution Medicines in a research note on Wednesday. Oppenheimer raised their price objective on shares of Revolution Medicines from $70.00 to $75.00 and gave the company an "outperform" rating in a research note on Thursday, May 8th. Needham & Company LLC reiterated a "buy" rating and set a $57.00 price objective on shares of Revolution Medicines in a research note on Thursday, May 8th. Finally, Wedbush reiterated an "outperform" rating and set a $67.00 price objective on shares of Revolution Medicines in a research note on Thursday, May 8th. Twelve analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has a consensus rating of "Buy" and a consensus price target of $67.08.

Revolution Medicines Price Performance

Shares of RVMD traded up $0.10 during trading hours on Friday, hitting $39.54. 2,061,263 shares of the company were exchanged, compared to its average volume of 1,498,571. The company has a market capitalization of $7.37 billion, a PE ratio of -11.01 and a beta of 1.11. The firm has a fifty day simple moving average of $37.49 and a 200-day simple moving average of $43.12. Revolution Medicines, Inc. has a one year low of $29.17 and a one year high of $62.40.

Revolution Medicines (NASDAQ:RVMD - Get Free Report) last released its quarterly earnings data on Wednesday, May 7th. The company reported ($1.13) earnings per share for the quarter, missing the consensus estimate of ($1.12) by ($0.01). During the same period last year, the company earned ($0.70) earnings per share. Sell-side analysts expect that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

Insider Transactions at Revolution Medicines

In other news, insider Mark A. Goldsmith sold 11,738 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $39.04, for a total transaction of $458,251.52. Following the completion of the sale, the insider now directly owns 441,564 shares of the company's stock, valued at $17,238,658.56. This trade represents a 2.59% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, CFO Jack Anders sold 1,864 shares of the firm's stock in a transaction on Monday, March 17th. The stock was sold at an average price of $39.04, for a total value of $72,770.56. Following the sale, the chief financial officer now directly owns 115,006 shares of the company's stock, valued at approximately $4,489,834.24. This represents a 1.59% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 16,660 shares of company stock valued at $650,406 in the last three months. 8.20% of the stock is currently owned by corporate insiders.

About Revolution Medicines

Revolution Medicines, Inc, a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline comprises RAS(ON) inhibitors designed to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors for combination treatment strategies.